The Ledger and the Laboratory

Opening Sermon · Fiction

FICTIONAL CONTINUITY: Epistide found a supply contract wearing a graduation cap. “Congratulations,” he said. “Which clinical trial did you pass?” The contract requested its lawyer.

Regulatory Gospel · Approval and policy

Compounding policy: The October 30 Federal Register notice formally announced HHS’s enforcement-discretion document for certain peptide substances. The notice calls it a draft, invites comments, and describes an interim approach while rulemaking continues. It does not grant FDA approval or establish clinical effectiveness. Compounded products remain outside FDA’s premarket review for safety, effectiveness and quality. Federal Register, October 30.

The accompanying policy names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Its conditions include identity and quality controls, adverse-event reporting and a single active ingredient. Consequently, inclusion of individual substances does not extend this policy to a combined “Wolverine” product. HHS policy and appendices, checked November 5.

RFK Jr.’s position—dated context: In October 20 remarks reported by Reuters, Kennedy argued for a regulated peptide market because Americans were already buying these products. The subsequent HHS document describes limited compounding under safeguards as a more controlled alternative to unregulated supply. This is the administration’s access and product-quality rationale; it is not new clinical evidence or proof that the policy will improve outcomes. Reuters, October 20 · HHS rationale, pages 1–2. No newer November statement was verified for this edition.

Approved human use: No new peptide approval or label expansion met this edition’s verification threshold.

Scientific Revelations · Controlled human evidence

Peer-reviewed evidence—an adjacent, non-peptide medicine: The October 30 ATTAIN-J publication reports a randomized, double-blind, placebo-controlled phase 3 study of oral orforglipron in 238 Japanese adults meeting the study’s obesity-disease criteria.

At 72 weeks, average weight reduction ranged from 5.9% to 8.7% across active-treatment groups, versus 0.6% with placebo, using the treatment-regimen estimand. Gastrointestinal symptoms predominated; nausea led to treatment discontinuation in approximately 2–8% across active groups.

These results concern this population and trial design. They do not establish superiority over semaglutide or tirzepatide, which were not comparators. Orforglipron is a small molecule, not a peptide. Yokote and colleagues, The Lancet Diabetes & Endocrinology, October 30.

Human Record · Observation and safety

Observational evidence pending fuller presentation: Novo’s October 29 announcement previews telehealth and digital-support studies assessing weight, treatment experience and “food noise,” alongside forthcoming STEP Young and CagriSema presentations. The conference is November 14–17; an announcement of future presentations is not a completed appraisal of their findings.

The same release identifies CagriSema and semaglutide use in children under 12 as investigational. Novo announcement, October 29.

Safety boundary: HHS’s reporting conditions create obligations to monitor problems. They do not supply reliable adverse-event rates or resolve the uncertainties surrounding these compounded peptides.

From the Laboratory · Evidence boundaries

Animal research: Ascletis announced a forthcoming ASC37 presentation concerning weight changes in mice and pharmacokinetics in nonhuman primates. This is a sponsor-announced preclinical program, not evidence of benefit in people.

In-vitro mechanisms: Its companion ASC48 presentation concerns laboratory and animal findings for a non-peptide GIP-receptor agonist. Neither announcement establishes a clinical treatment schedule or human safety. Ascletis release, November 2.

Resurfacing claim: This week’s “natural Ozempic” coverage revisits BRP research originally reported in March 2025. Stanford’s underlying work involved cells, mice and pigs. It does not establish a side-effect-free human alternative. Stanford, March 5, 2025; Resurfacing coverage, November 4.

Market Tithe · Profitide, fictional Keeper of the Market Tithe

FICTIONAL COMMENT—PROFITIDE: “The revenue is real. Please leave the miracle projections outside.”

Confirmed company disclosure: Novo Nordisk—NVO / NOVO-B—reported quarterly sales of DKK79.195 billion on November 4. Adjusted operating profit rose 27% at constant exchange rates, while reported operating profit fell 9%. The difference includes DKK8.7 billion in impairment charges, of which DKK4.1 billion concerns manufacturing-network resizing. Wegovy pill quarterly sales reached DKK5.394 billion. These are company financial results, not measures of comparative clinical benefit. Novo financial report, November 4.

Confirmed supply announcement: DataMEDS AI—MEDS—said its Corexa subsidiary entered a supply agreement covering six peptides. Its November dispensing start remained a plan in that release. The announcement establishes a company-reported agreement, not completed dispensing, independently verified compliance or FDA approval. Company release, November 2.

Dated market movement: Reuters reported Novo’s Copenhagen shares up 4.2% at 13:18 GMT on November 4. This is an intraday observation, not a closing return or proof that one announcement caused the movement. Reuters, November 4.

Editorial inference: Commercial activity is advancing alongside unresolved scientific questions. No additional material peptide-licensing announcement met this review’s verification threshold.

Movements in the Canon / Those Awaiting Canonization

No canon change or new character is proposed.

Further Reading · Deeper lecture

What a Launch Announcement Actually Proves

1. Enforcement discretion versus approval.

2. Supply agreements versus delivered products.

3. Controlled trials versus observational reports.

4. Animal findings versus human outcomes.

5. Reported profit versus adjusted profit.

Companion feature: TB-500—access changed. What did the evidence show?

Sacred Footnotes · Interests and limitations

Lilly funded ATTAIN-J; four authors disclose Lilly employment and share ownership. Novo, Ascletis and DataMEDS have direct commercial interests in their announcements. BRP researchers disclose relevant patents; senior investigator Katrin Svensson co-founded Merrifield Therapeutics.

ATTAIN-J’s abstract and disclosures were reviewed; the complete supplement was not. Upcoming conference findings require further appraisal. No independent clinical review has been completed.

Educational reporting only. No treatment, dosing, sourcing, medical or investment advice.